CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.
Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).
Healthcare
Biotechnology
Science
MedTech
Overview
Company Mission
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, is dedicated to developing and commercializing innovative oncolytic immunotherapies for bladder cancer patients. Our mission is to enhance the quality of life and dignity of urologic cancer patients through cutting-edge therapeutics.
Employees115
Hq LocationIrvine
Company values
Patient-Centered
Innovation
Team Collaboration
Integrity
Excellence
CG Oncology currently has 1 job on Remoteville
We sync with CG Oncology's jobs every 6 hours, so check again soon!
Recent Jobs
Remote Director, Finance & Accounting, United States- Oversee financial and accounting management including general ledger, receivables, payables, payroll, and benefits analysis. Lead and mentor the accounting te...